MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE
49.98
-0.12
-0.24%
Closed 19:57 12/04 EST
OPEN
49.96
PREV CLOSE
50.10
HIGH
50.76
LOW
49.77
VOLUME
14.24M
TURNOVER
0
52 WEEK HIGH
81.42
52 WEEK LOW
48.25
MARKET CAP
101.70B
P/E (TTM)
12.67
1D
5D
1M
3M
1Y
5Y
Blackstone explores sale of Anthos Therapeutics -sources
NASDAQ · 15h ago
Bristol-Myers Squibb Co: Statement of acquisition of beneficial ownership by individuals
Press release · 15h ago
Pfizer: This Year's Disaster Should Set The Stage For A Strong 2024
Pfizer has experienced a total return loss of nearly -40% in 2023. Downshifts in demand for covid-19 vaccines and antiviral products. Pfizer's stock is now trading at a significantly lower valuation compared to peers. 2023 has been a year to forget for pfizer, but the company's long-term growth prospects are bright. A dilutive $43 billion deal for seagen, a tornado destroying its north carolina production plant and trouble with its weight-loss drug development plan.
Seeking Alpha · 15h ago
After Hours Most Active for Dec 4, 2023 : BXSL, ENB, KEY, INTC, AMZN, BMY, C, MU, AAPL, BSX, GTLB, ETSY
NASDAQ · 17h ago
Geron: Lancet Publication Derisks Imetelstat Opportunity Narrowly Makes Bull Case
Geron corporation's lead candidate, imetelstat, has positive phase 3 data published in the lancet. Fda has accepted geron's nda and will convene an advisory committee to discuss the suitability for approval. Geron stock price is declining today despite the positive data being published in a respected journal.
Seeking Alpha · 19h ago
Insiders Buy the Holdings of VLUE ETF
NASDAQ · 22h ago
Weekly Report: what happened at BMY last week (1127-1201)?
Weekly Report · 1d ago
Biotechs post record gains in November amid improving outlook
Healthcare biotechs post record gains in november amid improving outlook. Gene therapy developers outperformed and pharma giants look for m&a opportunities in the industry. November was the best month for biotechs since november 2020. The spdr s&p biotech etf climbed 14% in november while the healthcare sector rose only 9%.
Seeking Alpha · 1d ago
More
About BMY
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.

Webull offers Bristol-Myers Squibb Co stock information, including NYSE: BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.